Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Authored Items
Keytruda Approved for Patients with Previously Treated Metastatic Small-Cell Lung Cancer
Yvette Florio Lane
Web Exclusives
in
FDA Oncology Update
First Chemoimmunotherapy Regimen Granted Accelerated Approval for Patients with Previously Treated DLBCL
Yvette Florio Lane
Web Exclusives
in
FDA Oncology Update
FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer
Yvette Florio Lane
Web Exclusives
in
Breast Cancer
,
FDA Oncology Update
Tibsovo Now FDA Approved as First-Line Treatment for AML with IDH1 Mutation
Yvette Florio Lane
Web Exclusives
in
FDA Oncology Update
FDA Approves Pembrolizumab plus Axitinib for Advanced Renal-Cell Carcinoma
Yvette Florio Lane
Web Exclusives
in
Renal-Cell Carcinoma
,
FDA Oncology Update
April 16, 2019 – FDA Approvals, News & Updates
Yvette Florio Lane
Web Exclusives
in
Lung Cancer
,
FDA Oncology Update
FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer
Yvette Florio Lane
Web Exclusives
in
Breast Cancer
,
FDA Oncology Update
Proposed Landmark Policy Changes to Modernize Mammography and Raise Breast Density Awareness
Yvette Florio Lane
Web Exclusives
in
Breast Cancer
,
FDA Oncology Update
FDA Approves Tecentriq plus Chemotherapy for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
Yvette Florio Lane
Web Exclusives
in
Lung Cancer
,
FDA Oncology Update
FDA Approves Tecentriq plus Abraxane—First Immunotherapy for PD-L1– Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Yvette Florio Lane
Web Exclusives
in
FDA Oncology Update
March 08, 2019 – FDA Approvals, News & Updates
Yvette Florio Lane
Web Exclusives
in
FDA Oncology Update
FDA Approves Pembrolizumab for Treatment of Advanced Melanoma
Yvette Florio Lane
Web Exclusives
in
FDA Oncology Update
FDA Approves Split-Dosing Regimen for Daratumumab in Patients with Multiple Myeloma
Yvette Florio Lane
Web Exclusives
in
FDA Oncology Update
February 8, 2019 - FDA Approvals, News & Updates
Yvette Florio Lane
Web Exclusives
in
FDA Oncology Update
February 1, 2019 - FDA Approvals, News & Updates
Yvette Florio Lane
Web Exclusives
in
FDA Oncology Update
Government Shutdown Impacts FDA Drug Approvals
Yvette Florio Lane
Web Exclusives
in
FDA Oncology Update
Last modified: June 13, 2019
